# Ebenbuild

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ebenbuild

- Industry: Healthcare IT
- Headquarters: Munich, Germany
- Website: www.ebenbuild.com
- Latest round: Seed (Mar 31, 2022)
- Investors on record: 2

## About

Based in Germany, founded in 2019 by its CEO Kei Müller, CTO Jonas Biehler, CSA Wolfgang Wall and CSA Karl-Robert Wichmann, Ebenbuild GmbH operates as a healthtech platform. In?July 2025,?Ebenbuild GmbH?received?EUR 2.3 million?in?grant?funding?from new investor?European Innovation Council. Ebenbuild provides digital twin-based precision therapeutic treatment for patients suffering from acute respiratory distress syndrome (ARDS). The company’s precision technology offers a protective ventilation strategy for each patient, preventing lung damage. Through predictive computer models, the company provides physics-based insights or treatment alternatives, allowing patients to improve their chances of survival and rehabilitation. The company plans to utilize the July 2025 funding to support the market introduction of Twinhale, an innovative software developed for pulmonary drug delivery.

## Funding rounds

- Seed, Mar 31, 2022 — High-Tech Gruenderfonds, Bayern Kapital

## Investors

- High-Tech Gruenderfonds (https://capitalatlas.ai/funds/high-tech-gruenderfonds) — Seed
- Bayern Kapital (https://capitalatlas.ai/funds/bayern-kapital) — Seed